Chapman Steven Leonard, the CEO of Natera, Inc., has sold shares of the company to meet tax obligations following the vesting of restricted stock units. This transaction, reported in a recent SEC filing, underscores the ongoing trends in executive compensation and stock management within the medical laboratory services sector.

Natera, Inc. is a prominent player in the medical laboratory services industry, focusing on genetic testing and diagnostics. The company, incorporated in Delaware, operates under the Central Index Key (CIK) number 0001604821. It has been actively filing with the SEC, including recent transactions reported on November 2, 2026, and prior filings throughout the year.

What the Filing Says

The SEC filing, accession number 0001711968-26-000030, details multiple transactions conducted by Leonard on November 2, 2026. He sold a total of 4,801 shares of Natera common stock at prices ranging from $387.90 to $415.64 per share. The filing notes, "The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs." This transaction aligns with a structured trading plan adopted by Leonard, which is intended to comply with Rule 10b5-1 under the Exchange Act.

Impact

This transaction may affect shareholders and stakeholders within Natera as it reflects the company's approach to managing executive compensation and stock transactions. The structured nature of the sale indicates a planned strategy in response to tax obligations, which can provide insights into the financial health and operational strategies of the company.

What's Next

The filing does not say what happens next.